Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant

Journal of Oncology Pharmacy Practice

Volumn 14, Issue 3, 2008, Pages 157-162

  Howell, Joshua E ^a   Szabatura, Audrea H ^b   Hatfield Seung, Amy ^a   Nesbit, Suzanne A ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Aprepitant; Encephalopathy; Ifosfamide; Neurotoxicity

Indexed keywords

ALBUMIN; APREPITANT; CREATININE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; IFOSFAMIDE; LORAZEPAM; MESNA; PROCHLORPERAZINE; ALKYLATING AGENT; ANTIDOTE; ANTIEMETIC AGENT; METHYLENE BLUE; MORPHOLINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG USE; FEMALE; HUMAN; INCIDENCE; LIVER FUNCTION TEST; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOMA; CHEMICALLY INDUCED DISORDER; DELIRIUM; KIDNEY FUNCTION TEST; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; TOXICITY AND INTOXICATION;

ANTIDOTES; ANTIEMETICS; ANTINEOPLASTIC AGENTS, ALKYLATING; DELIRIUM; FEMALE; HUMANS; IFOSFAMIDE; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; MALE; METHYLENE BLUE; MIDDLE AGED; MORPHOLINES; NEUROPSYCHOLOGICAL TESTS; NEUROTOXICITY SYNDROMES; RETROSPECTIVE STUDIES; SARCOMA;

EID: 58249094509     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155208093930     Document Type: Article

References (14)

1. Patel PN Methylene blue for management of ifosfamide-induced encephalopathy. Ann Pharmacother 2006; 40: 299-303.
2. David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Onc 2005; 28: 277-80.
3. Kerbusch T., de Kraker J., Keizer HJ et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 2001; 40: 41-62.
4. Meanwell CA, Blake AE, Kelly KA, Honigsberger L., Blackledge G. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986; 22: 815-9.
5. Warr D. The neurokinin-1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy. Expert Opin Pharmacother 2006; 7: 1653-58.
6. Durand J., Gourmel B., Mir O., Goldwasser F. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol 2007; 18: 808-9.
7. de Jonge ME, Huitema AD, Holtkamp MJ, van Dam SM, Beijnen JH, Rodenhuis S. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005; 56: 370- 8.
8. Tuma R., DeAngelis LM Altered mental status in patients with cancer. Arch Neurol 2000; 57: 1727-31.
9. Pelgrims J., De Vos F., Van den Brande J., Schrijvers D., Prové A., Vermorken JB Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: Report of 12 cases and a review of the literature. Br J Cancer 2000; 82: 291-4.
10. Edmonson J., Ryan L., Blum R. et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269-75.
11. Trzepacz P., Baker R., Greenhouse J. A symptom rating scale for delirium. J Psychiatr Res 1988; 23: 89-97.
12. Folstein M., Folstein S., McHugh P. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
13. Lobo A., Saz P., Marco G. et al. Revalidation and standardization of the Cognition Mini-Exam in the general geriatric population. Med Clin 1999; 112: 767-74.
14. Ferguson M., Stewart W., Cowie F., White J. Late-onset meningeal metastases in liposarcoma: A case report and review of the literature. Sarcoma 2006; 23039: 1-3.